BioCentury
ARTICLE | Emerging Company Profile

Targeting toxicity

Novonco ribonucleotide reductase, HMT inhibitors could be safer than predecessors

March 21, 2016 7:00 AM UTC

Novonco Therapeutics Inc. is developing a pipeline of targeted cancer therapies that were designed at City of Hope and University of California Irvine to be less toxic than either first-generation inhibitors, or parent molecules.

Its lead compound is COH29, a small molecule ribonucleotide reductase inhibitor that is slated to enter Phase I testing this year in solid tumors...